MX2012002172A - Anticuerpos contra el extodominio de erbb3 y usos de los mismos. - Google Patents

Anticuerpos contra el extodominio de erbb3 y usos de los mismos.

Info

Publication number
MX2012002172A
MX2012002172A MX2012002172A MX2012002172A MX2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A MX 2012002172 A MX2012002172 A MX 2012002172A
Authority
MX
Mexico
Prior art keywords
erbb3
antibodies
receptor
antigen binding
binding fragments
Prior art date
Application number
MX2012002172A
Other languages
English (en)
Other versions
MX336091B (es
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002172(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2012002172A publication Critical patent/MX2012002172A/es
Publication of MX336091B publication Critical patent/MX336091B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una nueva clase de anticuerpos y fragmentos de unión a antígeno de los mismos que se unen al dominio extracelular del receptor ErbB3 e inhiben diversas funciones de ErbB3. Por ejemplo, los anticuerpos y fragmentos de unión a antígeno descritos en la presente son capaces de unirse al receptor designado ErbB3 e inhibir la fosforilación mediada por ligando similar a EGF del receptor. Dichos anticuerpos y fragmentos de unión a antígeno de los mismos tiene la característica útil de inhibir la proliferación de células cancerígenas que expresan ErbB3.
MX2012002172A 2009-08-21 2010-08-23 Anticuerpos contra el extodominio de erbb3 y usos de los mismos. MX336091B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (en) 2009-08-21 2010-08-23 Antibodies against the ectodomain of erbb3 and uses thereof

Publications (2)

Publication Number Publication Date
MX2012002172A true MX2012002172A (es) 2012-05-29
MX336091B MX336091B (es) 2016-01-08

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002172A MX336091B (es) 2009-08-21 2010-08-23 Anticuerpos contra el extodominio de erbb3 y usos de los mismos.

Country Status (21)

Country Link
EP (1) EP2467164A2 (es)
JP (1) JP5752687B2 (es)
KR (1) KR20120059568A (es)
CN (1) CN103002912A (es)
AU (1) AU2010284018C1 (es)
BR (1) BR112012003809A2 (es)
CA (1) CA2771744A1 (es)
CR (1) CR20120108A (es)
DO (1) DOP2012000044A (es)
EA (1) EA201200195A1 (es)
EC (1) ECSP12011740A (es)
IL (1) IL218097A0 (es)
IN (1) IN2012DN01518A (es)
MA (1) MA33582B1 (es)
MX (1) MX336091B (es)
NI (1) NI201200027A (es)
PE (1) PE20121585A1 (es)
SG (1) SG178509A1 (es)
TN (1) TN2012000057A1 (es)
WO (1) WO2011022727A2 (es)
ZA (1) ZA201201195B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
KR101798679B1 (ko) 2010-03-11 2017-11-16 메리맥 파마슈티컬즈, 인크. ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US8481687B2 (en) 2010-04-09 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
SG187908A1 (en) 2010-08-20 2013-03-28 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
KR101862832B1 (ko) 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
BR112013027021A2 (pt) 2011-04-19 2016-11-29 Merrimack Pharmaceuticals Inc anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
KR20140033152A (ko) * 2011-06-20 2014-03-17 교와 핫꼬 기린 가부시키가이샤 항erbB3 항체
PH12014500483A1 (en) 2011-09-30 2014-04-14 Regeneron Pharma Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
JP6149042B2 (ja) * 2011-11-09 2017-06-14 ザ ユーエービー リサーチ ファンデーション Ｈｅｒ３抗体およびその使用
KR102083957B1 (ko) 2011-12-05 2020-03-04 노파르티스 아게 표피 성장 인자 수용체 3 (her3)에 대한 항체
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015058108A1 (en) * 2013-10-17 2015-04-23 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038609A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
WO2016038610A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017069628A2 (en) 2015-10-23 2017-04-27 Merus N.V. Binding molecules that inhibit cancer growth
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
SI3665198T1 (sl) 2017-08-09 2025-06-30 Merus N.V. Protitelesa, ki vežejo egfr in cmet
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
CN122011191A (zh) * 2020-10-14 2026-05-12 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
KR20230128271A (ko) * 2020-11-20 2023-09-04 악티늄 파마슈티컬즈, 인코포레이티드 고형 암의 치료를 위한 her3 방사선면역요법
IL309337A (en) * 2021-06-15 2024-02-01 Beijing Sinotau Bio Pharmaceuticals Tech Co Ltd Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof
WO2023198138A1 (zh) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 抗体或其抗原结合片段及其医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178789A1 (en) * 2007-02-16 2012-03-29 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
AU2010284018B2 (en) 2014-06-05
IL218097A0 (en) 2012-04-30
WO2011022727A2 (en) 2011-02-24
MA33582B1 (fr) 2012-09-01
ECSP12011740A (es) 2013-02-28
EA201200195A1 (ru) 2012-12-28
CN103002912A (zh) 2013-03-27
DOP2012000044A (es) 2012-06-30
NI201200027A (es) 2013-01-29
AU2010284018A1 (en) 2012-03-22
AU2010284018C1 (en) 2015-10-15
KR20120059568A (ko) 2012-06-08
WO2011022727A3 (en) 2013-06-27
BR112012003809A2 (pt) 2019-09-24
JP5752687B2 (ja) 2015-07-22
ZA201201195B (en) 2015-07-29
TN2012000057A1 (en) 2013-09-19
EP2467164A2 (en) 2012-06-27
CR20120108A (es) 2012-06-05
MX336091B (es) 2016-01-08
CA2771744A1 (en) 2011-02-24
JP2013506622A (ja) 2013-02-28
IN2012DN01518A (es) 2015-06-05
SG178509A1 (en) 2012-04-27
PE20121585A1 (es) 2012-11-29

Similar Documents

Publication Publication Date Title
TN2012000057A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2009008656A (es) Anticuerpos contra erbb3 y usos de los mismos.
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
MY181648A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
MX366223B (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
MX340683B (es) Anticuerpos anti-vla-4.
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
MX2013004897A (es) Anticuerpos y composiciones anti-her3.
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
NZ712903A (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
IN2014CN04373A (es)
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
IN2014DN09717A (es)
MX2015005756A (es) Proteinas de unión a antígeno anti-her3/her4 de unión a la horquilla beta de her3 y a la horquilla beta de her4.
IN2014CN04374A (es)
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
HK1166273A (en) Antibodies against the ectodomain of erbb3 and uses thereof